Articles tagged with Bone Cancer
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
The Association for Molecular Pathology recognizes Dartmouth Health medical director Laura J. Tafe for her exceptional leadership and dedication to the field of molecular diagnostics. She has been a member of the organization since 2007 and has held various positions, including president in 2023.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
Researchers found that increasing ADAR2 expression in osteosarcoma cells forces them to differentiate, slowing growth and invasive capacity. The treated cells began producing mineralized matrix, a hallmark of mature bone tissue. In mice, ADAR2-restored tumors were smaller and less invasive.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
A new international survey reveals that adults with hypophosphataemic osteomalacia face a substantial disease burden, often under-recognised. The study calls for improved awareness, education, and coordinated care to ensure timely diagnosis and optimal treatment.
Oregon Health & Science University has received significant NIH funding to develop advanced microphysiologic models that mimic how cancers grow and respond to treatment within bone tissues. Two new awards focus on osteosarcoma and prostate cancer, aiming to improve understanding of disease spread and treatment responses.
A new national study highlights the genetic changes that link exposure to Agent Orange to myelodysplastic syndromes, a group of bone marrow cancers that can progress to acute leukemia. The research found that exposed veterans were diagnosed at a younger age and had a higher rate of disease progression compared to unexposed patients.
Researchers at Case Western Reserve University have developed a new therapy called OSM CAR-T that successfully attacks osteosarcoma tumors in mouse models. This treatment harnesses the body's immune system to fight cancer, potentially offering better outcomes with fewer side effects than traditional chemotherapy.
The team will use SPARK THE MIDLANDS programme to advance healthcare research and develop a minimally invasive cancer-killing paste. The paste, made from gallium-doped bioglass, has shown a 99% success rate of eliminating cancerous cells and regenerating diseased bones.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers develop CAR T cell therapy that recognizes BCMA and BAFF-R proteins, providing a new approach to treating multiple myeloma. The treatment has shown promise in preclinical trials, with the potential to prevent relapse and extend lifespan.
Researchers at the University of Virginia Health System have developed a new treatment for acute myeloid leukemia, a deadly form of blood cancer. The FDA-approved medication works by disrupting cellular protein interactions that drive leukemia cell growth and survival, offering patients a potential cure.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
A Johns Hopkins-led study has found that two analgesic drugs, bupivacaine and rimegepant, can slow the growth of osteosarcoma tumors by inhibiting nerve signaling. The researchers tested these medications in mice with osteosarcoma-like tumors and observed a significant reduction in tumor growth and spread.
A recent study found that pazopanib helped 85% of young patients with multi-metastatic Ewing's sarcoma survive two years after diagnosis. The drug blocks the tumor's ability to grow new blood vessels, making tumors weaker and more sensitive to chemotherapy and radiation.
Researchers identified a previously unknown gene, SMARCAL1, that increases the risk of developing osteosarcoma in children and young adults. The study found that approximately 2.6% of children with osteosarcoma carry inherited mutations in SMARCAL1, which may weaken DNA repair and promote tumor growth.
A study led by Yibin Kang and Yujiao Han reveals that cancer cells hijack a specialized cell to recycle iron, depriving red blood cells of necessary iron and causing anemia. The discovery aims to slow down bone metastasis and alleviate complications.
The foundation provides $300,000 total funding over four years to investigate cancer causes, mechanisms, therapies, and prevention. This support fosters interdisciplinary research and encourages innovative projects that push boundaries and make breakthroughs.
Researchers evaluated clinical outcomes of endoscopic resection in sellar chondrosarcomas, revealing common symptoms like blurring of vision and headaches. The study also provides recommendations for accurate diagnosis using imaging data and clinical features.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new machine learning algorithm, SAVANA, has been developed to accurately detect structural variations in cancer genomes using long-read sequencing data. The algorithm was tested on 99 human tumour samples and showed high consistency with current clinical standards.
Researchers at MD Anderson Cancer Center have made significant discoveries in three key areas of cancer care. In a study on sickle cell disease, the team found that the disorder can suppress immunity by altering DNA structure in CD8+ T cells, leading to potential strategies for improving immunotherapy responses. Meanwhile, a biomarker-...
The release of long-read sequencing datasets for two Kids First studies provides a fuller understanding of how genetics contributes to childhood cancers and congenital disorders. The datasets include improved genome assembly capabilities, facilitating variant discovery and potential targeted therapy development.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
A highly sensitive bone marrow test has shown to double survival rates for patients with AML mutations in NPM1 and FLT3 genes, allowing for early detection of potential relapse. This trial indicates that regular molecular testing can improve long-term survival rates by restarting treatment earlier.
A novel bone marrow transplant process has been shown to be safe and curative for adults with sickle cell disease, offering a viable alternative to recent gene therapy products. The treatment, which uses a 'half-matched' donor, results in high cure rates and low side effects, making it a more accessible option for patients.
Researchers at Aston University and the Royal Orthopaedic Hospital are developing an injectable paste using gallium-doped bioglass to treat bone cancer. The substance has anticancer and bone regenerative properties, showing a 99% success rate in eliminating cancerous cells.
Osteosarcoma cells often have extra copies of the SETDB1 gene, making the cancer more aggressive and harder to treat. Blocking SETDB1 may help the immune system recognize and attack osteosarcoma cells, offering a promising new way to treat this type of bone cancer.
A new study identifies loss-translocation-amplification chromothripsis as a key mechanism driving osteosarcoma tumour development and evolution. This discovery has significant implications for treatment options and patient outcomes, highlighting the importance of investing in studies exploring cancer mechanisms.
Researchers have identified three distinct subtypes of osteosarcoma using advanced mathematical modeling and machine learning. This breakthrough could transform clinical trials and patient care by enabling targeted treatment personalized to individual cancer subtypes.
The new hospital will provide patient-centered care with personalized, compassionate treatment and groundbreaking research. Patients will have access to top specialists and pioneering therapies in cancer treatment.
Researchers at Johns Hopkins Medicine developed a potential novel treatment for breast cancer bone metastasis using RK-33, which targets and inhibits the protein DDX3. The drug successfully eliminated breast cancer bone metastases in lab models by controlling cancer cell growth and proliferation.
Scientists at Anglia Ruskin University are collaborating with Medannex to accelerate treatment for bone cancer in children, focusing on paediatric osteosarcoma. The first-in-class therapy MDX-124 has shown promising results in preclinical tests and is being evaluated in a clinical study.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center developed a biobank of 294 samples from 126 patients with 25 different subtypes of bone and soft tissue sarcoma. The team created tumor organoids that retained key characteristics of the original tumors, which were then subjected to high-throughput drug screening. They iden...
Researchers at Aston University have created a potential treatment for bone cancer using gallium-doped bioactive glasses, which has shown a 99% success rate in killing osteosarcoma cells. The therapy also promotes early stages of bone formation and regenerates diseased bones.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Scientists at St. Jude Children's Research Hospital identified two chemokines, CXCL8 and CXCL16, expressed by osteosarcoma that improved CAR T-cell homing. Modified cells expressing these chemokine receptors showed enhanced infiltration into tumors, leading to prolonged survival in a model of metastatic disease.
A new Europe-wide clinical framework aims to collect high-quality biological samples from patients, enabling researchers and clinicians to understand the genetic, biological, and other factors involved in childhood bone cancer. This will guide the development of tailored treatments for each patient's cancer type.
Researchers explore Extracellular signal-regulated kinase 5 (Erk5) and its unique structures regulating autophosphorylation and transcription. Erk5 is involved in angiogenesis, neurogenesis, energy metabolism, tumor growth, and metastasis, making it a potential target for cancer treatment.
A new type of immunotherapy has been developed to treat bone cancer osteosarcoma, with promising preclinical results in mice. The treatment uses gamma-delta T cells, which are less well-known immune cells that can be engineered to target tumours.
Researchers at UC Davis have updated their guidelines on neutering popular dog breeds, finding major differences in joint disorders and cancers. The study emphasizes personalized decisions, considering breed, sex, and context, and provides a table with guidelines for all 40 studied breeds.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Men with low sperm count or none have a higher risk of developing cancer, including at younger ages, compared to fertile men. Families of azoospermic men have a significantly increased risk of five cancers, while families of oligozoospermic men have a higher risk of colon, bone and joint, and testicular cancers.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.